高级检索
当前位置: 首页 > 详情页

HMGB1 exacerbates bronchiolitis obliterans syndrome via RAGE/NF-κB/HPSE signaling to enhance latent TGF-β release from ECM

| 认领 | 导出 |

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol, Ctr Biomed Res, Key Lab Organ Transplantat,Minist Hlth,Tongji Med, Minist Educ,Key Lab Organ Transplantat,Tongji Hos, Wuhan 430030, Peoples R China [2]Yangtze Univ, Coll Med, Dept Immunol, Clin & Mol Immunol Res Ctr, Jingzhou, Hubei, Peoples R China [3]Cent S Univ, Xiangya Hosp 2, Inst Emergency Med & Rare Dis, Dept Emergency Med, Changsha, Hunan, Peoples R China [4]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Sponsored Program Adm,Wuhan 430030,Peoples R China [5]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Infect Dis,Wuhan 430030,Peoples R China
出处:
ISSN:

关键词: Lung transplantation BOS HMGB1 RAGE/NF-kappa B pathway HPSE TGF-beta

摘要:
Bronchiolitis obliterans syndrome (BOS), characterized by progressive airflow obstruction, is the main barrier to long-term graft survival after lung transplantation. Despite extensive studies, the mechanisms underlying BOS remain poorly understood, and targeted interventions have not yet been fully developed. In the present study, we employed a mouse model of tracheal transplantation and demonstrated that blockade of HMGB1 alone or combined with heparanase (HPSE) attenuates the development of BOS. It was noted that HMGB1 was first passively released from necrotic/damaged cells as a result of early unavoidable allograft injuries, leading to macrophage infiltration along with HMGB1 active secretion. Mechanistic studies revealed that extracellular HMGB1 acted through its receptor, RAGE, to activate NF-kappa B, which then bound to the HPSE promoter to transcribe its expression. The enhanced HPSE next released HS-bonded latent TGF-beta from myofibroblast ECM by cleaving HS chains to promote the initiation and progression of BOS. Together, our data suggest that HMGB1 and HPSE could be viable targets for prevention and intervention of fibrotic diseases such BOS after lung transplantation.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 3 区 医学
小类 | 3 区 医学:研究与实验 3 区 肿瘤学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 肿瘤学
JCR分区:
出版当年[2014]版:
Q2 ONCOLOGY Q2 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q3 MEDICINE, RESEARCH & EXPERIMENTAL Q4 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol, Ctr Biomed Res, Key Lab Organ Transplantat,Minist Hlth,Tongji Med, Minist Educ,Key Lab Organ Transplantat,Tongji Hos, Wuhan 430030, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol, Ctr Biomed Res, Key Lab Organ Transplantat,Minist Hlth,Tongji Med, Minist Educ,Key Lab Organ Transplantat,Tongji Hos, Wuhan 430030, Peoples R China [4]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Dept Sponsored Program Adm,Wuhan 430030,Peoples R China [*1]Tongji Hosp,Ctr Biomed Res,1095 Jiefang Ave,Wuhan 430030,Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:590 今日访问量:1 总访问量:442 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)